Q1 Earnings Estimate for Neurogene Issued By Lifesci Capital

Neurogene Inc. (NASDAQ:NGNE) – Investment analysts at Lifesci Capital lowered their Q1 2026 earnings per share estimates for Neurogene in a note issued to investors on Tuesday, March 24th. Lifesci Capital analyst P. Dolezal now anticipates that the company will post earnings per share of ($1.26) for the quarter, down from their prior forecast of ($1.19). Lifesci Capital currently has a “Outperform” rating and a $50.00 target price on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. Lifesci Capital also issued estimates for Neurogene’s Q2 2026 earnings at ($1.28) EPS, Q3 2026 earnings at ($1.04) EPS, Q4 2026 earnings at ($1.06) EPS and FY2026 earnings at ($4.59) EPS.

Several other equities research analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Neurogene in a research note on Tuesday, January 13th. Canaccord Genuity Group started coverage on Neurogene in a report on Friday, February 27th. They set a “buy” rating for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a research note on Thursday, January 22nd. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $44.00.

Neurogene Stock Performance

Shares of NGNE opened at $22.03 on Thursday. Neurogene has a twelve month low of $6.88 and a twelve month high of $37.27. The firm’s 50 day moving average price is $19.39 and its two-hundred day moving average price is $21.65. The firm has a market cap of $341.24 million, a P/E ratio of -5.20 and a beta of 1.53.

Neurogene (NASDAQ:NGNE) last issued its quarterly earnings data on Tuesday, March 24th. The company reported ($1.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.20) by $0.08.

Insider Activity at Neurogene

In other news, insider Stuart Cobb sold 6,797 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $20.81, for a total transaction of $141,445.57. Following the completion of the transaction, the insider directly owned 30,497 shares of the company’s stock, valued at $634,642.57. This trade represents a 18.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Christine Mikail Cvijic sold 4,045 shares of Neurogene stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $20.81, for a total transaction of $84,176.45. Following the completion of the sale, the chief financial officer owned 105,798 shares in the company, valued at $2,201,656.38. This trade represents a 3.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 11.64% of the stock is owned by company insiders.

Institutional Investors Weigh In On Neurogene

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtus Investment Advisers LLC boosted its stake in shares of Neurogene by 128.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 12,716 shares of the company’s stock worth $262,000 after buying an additional 7,138 shares during the last quarter. Logos Global Management LP acquired a new stake in shares of Neurogene in the fourth quarter valued at about $4,017,000. Schonfeld Strategic Advisors LLC bought a new stake in Neurogene during the fourth quarter worth about $575,000. Trexquant Investment LP raised its holdings in Neurogene by 9.7% during the fourth quarter. Trexquant Investment LP now owns 43,323 shares of the company’s stock worth $892,000 after acquiring an additional 3,840 shares in the last quarter. Finally, Blair William & Co. IL boosted its position in Neurogene by 15.4% during the fourth quarter. Blair William & Co. IL now owns 163,655 shares of the company’s stock valued at $3,371,000 after purchasing an additional 21,835 shares during the last quarter. 52.37% of the stock is owned by institutional investors.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.